Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$5.88 USD
+0.26 (4.63%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $5.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AUPH 5.88 +0.26(4.63%)
Will AUPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Other News for AUPH
Aurinia Pharma Q2 2024 Earnings Preview
Notable earnings before Thursday's open
Noteworthy Monday Option Activity: AUPH, BYON, WCC
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
Aurinia Pharmaceuticals Announces Q2 Results Date